Business
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
With new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now covered by all major
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nWith new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now covered by all major commercial health insurers\n\n\n\nOnly blood test approved by FDA as companion diagnostic for ORSERDU™ (elacestrant), Guardant360 CDx gains coverage by Aetna and Humana to identify eligible patients with advanced breast cancer prior to initiation of treatment\n\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the Guardant360 liquid biopsy test from Anthem Blue Cross and Blue Shield, Aetna and Humana. With this additional coverage, Guardant360 CDx/Guardant360 is now covered for comprehensive genomic profiling by all major U.S. commercial health insurers.\n\n\nThe Guardant360 CDx/Guardant360 test analyzes circulating tumor DNA (ctDNA) to provide comprehensive genomic profiling, or tumor mutation profiling, for all solid tumors. It is used by healthcare professionals to detect actionable cancer biomarkers in a patient’s blood that may help inform their therapy selection.\n\n\n“We are pleased that these major health insurers have taken this step to improve access to comprehensive genomic profiling for their patients with advanced cancers,” said Helmy Eltoukhy, Guardant Health co-CEO. “The Guardant360 blood test can help oncologists quickly identify the specific mutations driving cancer in order to select the most appropriate therapy. We believe this recognition of the clinical value of our test will result in improved outcomes for more patients with cancer.”\n\n\nIn February, Guardant Health announced that it had received coverage from UnitedHealthcare for Guardant360 CDx as companion diagnostic in advanced lung and breast cancer. Over the past few weeks, the Guardant360 test has received commercial policy coverage from three additional major U.S. health insurers.\n\n\nThe Guardant360 test received coverage under Anthem Blue Cross and Blue Shield commercial health insurance policies for complete genomic profiling of any solid tumor to identify actionable biomarkers to inform therapy selection. Anthem operates in 14 states and provides 32 million individuals with access to more than 1.7 million doctors and hospitals nationwide through Anthem...